High lapatinib plasma levels in breast cancer patients: risk or benefit?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A33141415" target="_blank" >RIV/61989592:15110/12:33141415 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/12:33141058 RIV/00098892:_____/12:#0000222
Result on the web
<a href="http://dx.doi.org/10.1700/1053.11516" target="_blank" >http://dx.doi.org/10.1700/1053.11516</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1700/1053.11516" target="_blank" >10.1700/1053.11516</a>
Alternative languages
Result language
angličtina
Original language name
High lapatinib plasma levels in breast cancer patients: risk or benefit?
Original language description
Aims and background. Lapatinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptors 1 (EGFR/HER1) and 2 (HER2) used in the treatment of patients with HER2-positive breast cancer. The aim of the present study was to determine lapatinib plasma levels in breast cancer patients treated with lapatinib plus capecitabine.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Tumori
ISSN
0300-8916
e-ISSN
—
Volume of the periodical
98
Issue of the periodical within the volume
1
Country of publishing house
IT - ITALY
Number of pages
4
Pages from-to
162-165
UT code for WoS article
—
EID of the result in the Scopus database
—